Boehringer Ingelheim Appoints General Manager of Pawru, Inc.

DULUTH, Ga., July 14, 2021 /PRNewswire/ -- Boehringer Ingelheim Animal Health USA Inc. has appointed Bryan Haardt as General Manager of Pawru, Inc., a Boehringer Ingelheim company that facilitates collaborative pet care by connecting veterinary professionals and pet owners on an innovative digital platform.

Pawru helps veterinary clinics grow their business while helping pet owners ensure the best care for animals.  Pet owners experience the service as a mobile app that links them with veterinarians for telemedicine appointments, prescription refills, messaging, pet health care content and more. Boehringer Ingelheim announced this year that it had created Pawru as a separate company and would re-brand a service that the company offered nationwide in 2020 as PetPro Connect.

"We live in a rapidly changing world where technology is transforming the way we care for pets," said Randolph Legg, President and Head of Commercial Business at Boehringer Ingelheim Animal Health USA Inc. "Bryan's leadership expertise and passion for digital health innovation will help us accelerate Pawru's offerings for the connected community of all who care for pets."

Haardt is the co-founder and former chief executive officer of Decisio Health Inc., a healthcare IT company that delivers actionable information through digital solutions to improve healthcare. Those solutions include the first web-native, real-time clinical surveillance and data visualization platform to receive FDA 510(K) class II clearance.

Haardt also has served as chief operating officer of Prognosis Health Information Systems, Inc. and held executive-level positions at Cgate Health, Inc., ClinicStation, and 10X Labs, Inc.

Boehringer Ingelheim Animal Health 
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both. 

Respect for animals, humans and the environment guides us every day. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases. 

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.7 billion (4.1 billion euros) in 2020 and presence in more than 150 countries. 

Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.

Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, with around 52,000 employees, we create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros). Our significant investment of over $4.2 billion (3.7 billion euros) in 2020 (18.9% of net sales) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

SOURCE Boehringer Ingelheim, Inc.